Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma

Author(s): Maurizio Zangari, Federica Cavallo and Guido Tricot

Volume 7, Issue 6, 2006

Page: [449 - 453] Pages: 5

DOI: 10.2174/138920106779116838

Price: $65

Abstract

Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of long-lived neoplastic plasma cells (PC) within the bone marrow (BM). Novel treatments are not only targeting myeloma cells but also directly interfere with myeloma-stromal cell interactions, interrupting signal transduction pathways. Farnesyltransferase inhibitors (FTIs) and rapamycin represent novel classes of signal transduction inhibitors targeting principally Ras/MAPK and PI3K/Akt pathway. Pre-clinical and early clinical reports are presented in this study.

Keywords: CAAX binding site, Tipifarnib, STAT3 tyrosine phosphorylation, mTOR Kinase pathway, CCI-779, haematological malignancies


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy